Artery Therapeutics

Artery Therapeutics, Inc. (Artery), a biotechnology company headquartered in the San Francisco Bay area, develops proprietary therapeutics for cardiovascular disease (CVD). Now Artery is applying its technical and metabolic know-how to developing treatments for diabetes-generated cardiovascular disease and neurodegenerative diseases. Artery's novel peptide library is derived from apolipoprotein E (ApoE). Our safe and effective peptides are designed to manipulate the ABCA1 (ATP-binding cassette) transporter, thereby altering cell membrane functionality and lipid composition. The clinical candidate programs for neurodegenerative diseases and diabetes-generated cardiovascular disease are investigational new drug (IND) ready.